Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 4.79% is 45% below its 5-year average of 8.73%, near the low end of its 5-year range (0.73%–15.92%).
As of the fiscal period ended Tuesday, June 30, 2026. 30.07% below its 12-month average of 6.85%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 4.79%.
DEBT TO ASSETS RATIO
4.79%
DEBT TO ASSETS RATIO AVG TTM
6.85%
DEBT TO ASSETS RATIO AVG 3Y
10.06%
DEBT TO ASSETS RATIO AVG 5Y
8.73%
DEBT TO ASSETS RATIO AVG 10Y
7.20%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-30.07%
CURRENT VS 3Y AVG
-52.37%
CURRENT VS 5Y AVG
-45.11%
CURRENT VS 10Y AVG
-33.44%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+5224.66%
vs the sector median at left
Solid Biosciences Inc.
Market Cap
$681.27M
Debt to Assets Ratio
4.79%
TTM Avg
6.85%
3Y Avg
10.06%
5Y Avg
8.73%
Market Cap
$685.49M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$673.41M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$691.79M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$693.19M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$693.61M
Debt to Assets Ratio
0.08%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$694.79M
Debt to Assets Ratio
0.06%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | $681.27M | 4.79% | 6.85% | 10.06% | 8.73% |
| Verastem, Inc. (VSTM)vs › | $681.02M | 0.41% | N/A | N/A | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $685.49M | 0.01% | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $673.41M | 0.01% | N/A | N/A | N/A |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $691.79M | 0.00% | N/A | N/A | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $693.19M | 0.00% | N/A | N/A | N/A |
| Wave Life Sciences Ltd. (WVE)vs › | $693.61M | 0.08% | N/A | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $694.79M | 0.06% | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $666.95M | 0.00% | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $660.29M | 0.10% | N/A | N/A | N/A |
Debt/Assets
4.8%
Debt/Equity
0.05
Current Ratio
13.82
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 4.79% |
| 2026-03-31 | 4.89% |
| 2025-12-31 | 9.10% |
| 2025-09-30 | 8.01% |
| 2025-06-30 | 7.48% |
| 2025-03-31 | 6.87% |
| 2024-12-31 | 12.81% |
| 2024-09-30 | 11.67% |
| 2024-06-30 | 10.95% |
| 2024-03-31 | 10.38% |
| 2023-12-31 | 15.92% |
| 2023-09-30 | 14.53% |
| 2023-06-30 | 13.38% |
| 2023-03-31 | 12.09% |
| 2022-12-31 | 10.97% |
| 2022-09-30 | 13.93% |
| 2022-06-30 | 11.98% |
| 2022-03-31 | 0.73% |
| 2021-12-31 | 0.89% |
| 2021-09-30 | 0.91% |
| 2021-06-30 | 1.05% |
| 2021-03-31 | 1.62% |
| 2020-12-31 | 3.01% |
| 2020-09-30 | 13.95% |
| 2020-06-30 | 10.60% |
| 2020-03-31 | 8.94% |
| 2019-12-31 | 6.83% |
| 2019-09-30 | 10.05% |
| 2019-06-30 | 14.60% |
| 2019-03-31 | 12.10% |
| 2018-12-31 | 1.35% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2016-12-31 | 0.00% |
